Cellular and molecular basis of KMT2A/MLL leukaemias: From transformation mechanisms to novel therapeutic strategies

Chromosomal Translocations and Genome Rearrangements in Cancer

Volumn , Issue , 2015, Pages 223-250

  Zeisig, Bernd B ^a   So, Chi Wai Eric ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute leukaemia; Cell of origin; Epigenetics; KMT2A MLL leukaemia stem cells; Targeted therapy

Indexed keywords

EID: 85016821680     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-19983-2_11     Document Type: Chapter

References (142)

1. Tamai H, Inokuchi K (2010) 11q23/MLL acute leukemia: update of clinical aspects. J Clin Exp Hematopathol: JCEH 50(2): 91-98
2. Zeisig BB et al (2012) SnapShot: acute myeloid leukemia. Cancer Cell 22(5): 698-698, e1
3. Manola KN (2013) Cytogenetic abnormalities in acute leukaemia of ambiguous lineage: an overview. Br J Haematol 163: 24-39
4. Pui C, Robison L, Look A (2008) Acute lymphoblastic leukaemia. Lancet 371: 1030-1043
5. Greaves M, Wiemels J (2003) Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 3(9): 639-649
6. Hunger S, Sklar J, Link M (1992) Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the literature. J Clin Oncol: Off J Am Soc Clin Oncol 10(1): 156-163
7. Meyer C et al (2013) The MLL recombinome of acute leukemias in 2013. Leukemia 27(11): 2165-2176
8. Zeisig DT et al (2005) The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 24(35): 5525-5532
9. Bitoun E, Oliver P, Davies K (2007) The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 16(1): 92-106
10. Mueller D et al (2007) A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110(13): 4445-4454
11. Lin C et al (2010) AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 37(3): 429-437
12. Yokoyama A et al (2010) A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17(2): 198-212
13. Mohan M et al (2010) Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev 24(6): 574-589
14. Martin M et al (2003) Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell 4(3): 197-207
15. Bernot KM et al (2013) Eradicating acute myeloid leukemia in a Mll(PTD/wt): Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. Blood 122(23): 3778-3783
16. Zorko NA et al (2012) Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood 120(5): 1130-1136
17. Zhang Y et al (2012) Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood 120(5): 1118-1129
18. Dohner K (2002) Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20: 3254-3261
19. Yip B, So C (2013) Mixed lineage leukemia protein in normal and leukemic stem cells. Exp Biol Med (Maywood) 238(3): 315-323
20. Espinet B et al (2003) MLL intrachromosomal amplification in a pre-B acute lymphoblastic leukemia. Haematologica 88(2): 28-29
21. Ziemin-van der Poel S et al (1991) Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A 88(23): 10735-10739
22. Gu Y et al (1992) The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 71(4): 701-708
23. Djabali M et al (1992) A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 2(2): 113-118
24. Corral J et al (1996) An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 85(6): 853-861
25. Lavau C et al (1997) Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 16(14): 4226-4237
26. Yeung J et al (2010) β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18: 606-618
27. Collins E et al (2000) Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development. EMBO Rep 1(2): 127-132
28. Drynan L et al (2005) Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis. EMBO J 24(17): 3136-3146
29. Forster A et al (2003) Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 3(5): 449-458
30. Zeisig BB et al (2004) Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 24(2): 617-628
31. Horton S et al (2005) Continuous MLL-ENL expression is necessary to establish a “Hox Code” and maintain immortalization of hematopoietic progenitor cells. Cancer Res 65(20): 9245-9252
32. Wei J et al (2008) Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 13(6): 483-495
33. Barabé F et al (2007) Modeling the initiation and progression of human acute leukemia in mice. Science (New York) 316(5824): 600-604
34. So C et al (2003) MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 3(2): 161-171
35. Chen W (2006) A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 108: 669-677
36. Metzler M et al (2006) A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 25(22): 3093-3103
37. Greaves MF, So CW (2006) Alert and sniffy-nosed about Mll-AF4? Blood 108: 416-417
38. Krivtsov AV et al (2008) H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14(5): 355-368
39. Zeisig BB et al (2008) Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia. Cancer Cell 14(5): 345-347
40. Bursen A et al (2010) The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood 115(17): 3570-3579
41. Kumar AR et al (2011) Authors’ comments: t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL. Leuk Res 35(5): 697
42. Kowarz E et al (2007) Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4.MLL fusion allele. Leukemia 21(6): 1232-1238
43. Zeisig BB et al (2003) The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell. Oncogene 22(11): 1629-1637
44. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL (2003) Similar MLL-associated leukemias arising from selfrenewing stem cells and short-lived myeloid progenitors. Genes Dev 17: 3029-3035
45. Krivtsov AV et al (2006) Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442(7104): 818-822
46. Somervaille T et al (2009) Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4(2): 129-140
47. Chen W et al (2008) Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 13(5): 432-440
48. Urnov F et al (2005) Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435(7042): 646-651
49. Miller J et al (2011) A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29(2): 143-148
50. Moehrle A, Paro R (1994) Spreading the silence: epigenetic transcriptional regulation during Drosophila development. Dev Genet 15: 478-484
51. Yu B et al (1995) Altered hox expression and segmental identity in Mll-mutant mice. Nature 378(6556): 505-508
52. Nislow C, Ray E, Pillus L (1997) SET1, a yeast member of the trithorax family, functions in transcriptional silencing and diverse cellular processes. Mol Biol Cell 8(12): 2421-2436
53. Roguev A et al (2001) The Saccharomyces cerevisiae Set1 complex includes an Ash2 homologue and methylates histone 3 lysine 4. EMBO J 20(24): 7137-7148
54. Milne T et al (2002) MLL targets SET domain methyltransferase activity to hox gene promoters. Mol Cell 10(5): 1107-1117
55. Smith ST et al (2004) Modulation of heat shock gene expression by the TAC1 chromatinmodifying complex. Nat Cell Biol 6: 162-167
56. Terranova R et al (2006) Histone and DNA methylation defects at hox genes in mice expressing a SET domain-truncated form of Mll. Proc Natl Acad Sci U S A 103(17): 6629-6634
57. Mohan M et al (2010) Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 10(10): 721-728
58. Mohan M et al (2011) The COMPASS family of H3K4 methylases in Drosophila. Mol Cell Biol 31(21): 4310-4318
59. Muntean A et al (2010) The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 17(6): 609-621
60. Dawson M et al (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370): 529-533
61. Yokoyama A et al (2005) The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123(2): 207-218
62. So C et al (2003) Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 4: 99-110
63. Eguchi M, Eguchi-Ishimae M, Greaves M (2004) The small oligomerization domain of gephyrin converts MLL to an oncogene. Blood 103(10): 3876-3882
64. Cheung N et al (2007) Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 9(10): 1208-1215
65. Wang Q-F et al (2011) MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 117(25): 6895-6905
66. Bernt K et al (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20(1): 66-78
67. Guenther M et al (2008) Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev 22(24): 3403-3408
68. Milne T et al (2010) Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell 38(6): 853-863
69. Thiel A et al (2010) MLL-AF9-induced leukemogenesis requires coexpression of the wildtype Mll allele. Cancer Cell 17(2): 148-159
70. Jude C et al (2007) Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 1(3): 324-337
71. McMahon K et al (2007) Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 1(3): 338-345
72. Mishra BP et al (2014) The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Cell Rep 7: 1239-1247
73. Tanabe S et al (1996) Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line. Genes Chromosomes Cancer 15(4): 206-216
74. Ono R et al (2005) Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest 115(4): 919-929
75. Armstrong S et al (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30(1): 41-47
76. Armstrong S et al (2003) Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3(2): 173-183
77. Knapper S (2011) The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig Drugs 20(10): 1377-1395
78. Albouhair S, Morgado E, Lavau C (2013) Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes. PLoS One 8(8): e72261
79. Montes R et al (2013) Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells. Leukemia 28: 666-674
80. Hess JL et al (2006) c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 108(1): 297-304
81. Wong P et al (2007) Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 21(21): 2762-2774
82. Schwieger M et al (2009) Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. Blood 114(12): 2476-2488
83. Faber J et al (2009) HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113(11): 2375-2385
84. Ayton P, Cleary M (2003) Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17(18): 2298-2307
85. So C et al (2004) Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 103(8): 3192-3199
86. Kumar AR et al (2004) Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood 103(5): 1823-1828
87. Jiang X et al (2012) MiR-495 is a tumor-suppressor microRNA down-regulated in MLLrearranged leukemia. Proc Natl Acad Sci U S A 109(47): 19397-19402
88. Huang H et al (2013) TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A 110(29): 11994-11999
89. Chen P et al (2013) miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A 110(28): 11511-11516
90. Bindels E et al (2012) EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood 119(24): 5838-5849
91. Mikesch JH et al (2007) The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia 21: 1638-1647
92. Wang Y et al (2010) The Wnt/β catenin pathway is required for the development of leukemia stem cells in AML. Science 327: 1650-1653
93. Jeannet G et al (2008) Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood 111(1): 142-149
94. Koch U et al (2008) Simultaneous loss of beta-and gamma-catenin does not perturb hematopoiesis or lymphopoiesis. Blood 111(1): 160-164
95. Fung T, Gandillet A, So C (2012) Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/β-catenin pathway. Curr Opin Hematol 19(4): 280-286
96. Heidel F et al (2012) Genetic and pharmacologic inhibition of β-catenin targets imatinibresistant leukemia stem cells in CML. Cell Stem Cell 10(4): 412-424
97. Zhao C et al (2007) Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12(6): 528-541
98. Jamieson CH et al (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351(7): 657-667
99. Miller P et al (2013) In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell 24(1): 45-58
100. Zeisig BB, So CW (2013) Linking MLL leukemia with integrin signaling. Cancer Cell 24(1): 5-7
101. Mócsai A, Ruland J, Tybulewicz V (2010) The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 10(6): 387-402
102. Zeisig BB et al (2011) Collaboration between PcG proteins and MLL fusions in leukemogenesis: an emerging paradigm. Cancer Cell 20(5): 551-553
103. Smith LL et al (2011) Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 8(6): 649-662
104. García-Cuéllar M et al (2001) The ENL moiety of the childhood leukemia-associated MLLENL oncoprotein recruits human Polycomb 3. Oncogene 20(4): 411-419
105. Tan J et al (2011) CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 20(5): 563-575
106. Maethner E et al (2013) MLL-ENL inhibits polycomb repressive complex 1 to achieve effi-cient transformation of hematopoietic cells. Cell Rep 3(5): 1553-1566
107. Neff T et al (2012) Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A 109(13): 5028-5033
108. Tanaka S et al (2012) Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 120(5): 1107-1117
109. Huang G et al (2011) The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood 118(25): 6544-6552
110. Goyama S et al (2013) Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest 123(9): 3876-3888
111. Wilkinson A et al (2013) RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep 3(1): 116-127
112. Zhao X et al (2014) Down-regulation of RUNX1/CBFβ by MLL fusion proteins enhances HSC self-renewal. Blood 123: 1729-1738
113. Ohlsson E et al (2014) Initiation of MLL-rearranged AML is dependent on C/EBPα. J Exp Med 211(1): 5-13
114. Zhou J et al (2013) PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/ HOX pathway. Leukemia 28(7): 1436-1438
115. Kuo H-P et al (2013) Epigenetic roles of MLL oncoproteins are dependent on NF-κB. Cancer Cell 24(4): 423-437
116. Wang E et al (2013) Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proc Natl Acad Sci U S A 110(10): 3901-3906
117. Kagoya Y et al (2014) Positive feedback between NF-κB and TNF-α promotes leukemiainitiating cell capacity. J Clin Invest 124(2): 528-542
118. Dreyer Z et al (2011) Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children’s Oncology Group. J Clin Oncol: Off J Am Soc Clin Oncol 29(2): 214-222
119. Mann G et al (2010) Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 study. Blood 116(15): 2644-2650
120. Jo S et al (2011) Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 117(18): 4759-4768
121. Nguyen A et al (2011) DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117(25): 6912-6922
122. Nguyen A et al (2011) Essential role of DOT1L in maintaining normal adult hematopoiesis. Cell Res 21(9): 1370-1373
123. Daigle S et al (2011) Selective killing of mixed lineage leukemia cells by a potent smallmolecule DOT1L inhibitor. Cancer Cell 20(1): 53-65
124. Yu W et al (2012) Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 3: 1288
125. Daigle S et al (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122(6): 1017-1025
126. Harris W et al (2012) The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21(4): 473-487
127. Schenk T et al (2012) Inhibition of the LSD1 (KDM1A) demethylase reactivates the alltrans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 18(4): 605-611
128. Zuber J et al (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478(7370): 524-528
129. Filippakopoulos P et al (2010) Selective inhibition of BET bromodomains. Nature 468(7327): 1067-1073
130. Nicodeme E et al (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468(7327): 1119-1123
131. Kim J et al (2010) A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143(2): 313-324
132. Dawson M et al (2014) Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 28(2): 311-320
133. Wyspiańska B et al (2014) BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Leukemia 28(1): 88-97
134. Chandrasekharappa S, Teh B (2003) Functional studies of the MEN1 gene. J Intern Med 253(6): 606-615
135. Huang J et al (2012) The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482(7386): 542-546
136. Grembecka J et al (2012) Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 8(3): 277-284
137. Shi A et al (2012) Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 120(23): 4461-4469
138. Dou Y et al (2006) Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol 13(8): 713-719
139. Cao F et al (2014) Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell 53(2): 247-261
140. Muntean A et al (2013) MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction. Blood 122(11): 1914-1922
141. Malik R et al (2015) Targeting the MLL complex in castration-resistant prostate cancer. Nat Med 21(4): 344-352
142. Borkin D et al (2015) Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 27: 589-602